ADV7103 + Standard of Care
Phase 2/3Withdrawn 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystinuria
Conditions
Cystinuria
Trial Timeline
May 1, 2024 → Aug 1, 2025
NCT ID
NCT04137978About ADV7103 + Standard of Care
ADV7103 + Standard of Care is a phase 2/3 stage product being developed by Advicenne for Cystinuria. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04137978. Target conditions include Cystinuria.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04137978 | Phase 2/3 | Withdrawn |
Competing Products
5 competing products in Cystinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1353 | Synlogic | Phase 1 | 25 |
| Pegtibatinase | Travere Therapeutics | Phase 3 | 72 |
| Pegtibatinase + Placebo | Travere Therapeutics | Phase 1/2 | 36 |
| Pegtibatinase | Travere Therapeutics | Phase 3 | 72 |
| ADV7103 + Placebo | Advicenne | Phase 2/3 | 57 |